We observedno findings strong enough to support the use of these molecules as markers of disease stage or cachexia.CONCLUSION: Resistin, visfatin, and chemerin cannot be used as potential biomarkers for lung cancer or COPD or for disease stageor cachexia.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:OBJECTIVES: Cachexia is an important problem in lung cancer and chronic obstructive pulmonary disease (COPD).
📊
Key Findings & Data:Our study aimed to investigate the association of three novel adipokines, resistin, visfatin, and chemerin, with lung cancer and COPD.MATERIALS AND METHODS: 30 patients with non-smallcell lung cancer, 30 patients with COPD, and 30 healthy volunteers wereincluded in the study.
💡
Conclusion & Impact:We observedno findings strong enough to support the use of these molecules as markers of disease stage or cachexia.CONCLUSION: Resistin, visfatin, and chemerin cannot be used as potential biomarkers for lung cancer or COPD or for disease stageor cachexia.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
OBJECTIVES: Cachexia is an important problem in lung cancer and chronic obstructive pulmonary disease (COPD). Some studies reportan association between adipokines and cachexia. Our study aimed to investigate the association of three novel adipokines, resistin, visfatin, and chemerin, with lung cancer and COPD.MATERIALS AND METHODS: 30 patients with non-smallcell lung cancer, 30 patients with COPD, and 30 healthy volunteers wereincluded in the study. Statistically significant weight loss was found in COPD and lung cancer groups compared with that in the controlgroup (p 0.05). We observedno findings strong enough to support the use of these molecules as markers of disease stage or cachexia.CONCLUSION: Resistin, visfatin, and chemerin cannot be used as potential biomarkers for lung cancer or COPD or for disease stageor cachexia.
🔖
Cite This Article
GÖKTEPE, M., KORKMAZ, C., ZAMANİ, A., DEMİRBAŞ, S., KILINÇ, İ. (2020). Evaluation of Serum Resistin, Visfatin, and Chemerin Levels in Patients with Lung Cancer and Chronic Obstructive Pulmonary Disease. Turkish Thoracic Journal, Cilt: 21 - Sayı: 3, 169–173. https://ajindex.com/articles/417977
Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013
[Crossref] 2. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2002
[Crossref] 3. Ntikoudi E, Kiagia M, Boura P, et al. Hormones of adipose tissue and their biologic role in lung cancer. Cancer Treat Rev 2014
[Crossref] 4. Karapanagiotou EM, Tsochatzis EA, Dilana KD, et al. The significance of leptin, adiponectin, and resistin serum levels in nonsmall cell lung cancer (NSCLC). Lung Cancer 2008
[Crossref] 5. Broekhuizen R, Vernooy J, Schols A, et al. Leptin as local inflammatory marker in COPD. Respir Med 2005
[Crossref] 6. Housa D, Housova J, Vernerova Z, et al. Adipocytokines and cancer. Physiol Res 2006
Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 2011
[Crossref] 8. Goldstraw P, Crowley JJ. The International Association for the Study of Lung Cancer international staging project on lung cancer. J Thorac Oncol 2006
[Crossref] 9. Kocabaş A, Atış S, Çöplü L, et al. Kronik obstrüktif akciğer hastaliği (KOAH) koruma, tani ve tedavi raporu 2014. J Turkish Thorac Society 2014
S19-S29. 10. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994
[Crossref] 11. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000
[Crossref] 12. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 2011
[Crossref] 13. Weryńska B, Kosacka M, Go ecki M, et al. Leptin serum levels in cachectic and non-cachectic lung cancer patients. Adv Respir Med 2009
Hajri T, Gharib M, Kaul S, et al. Association between adipokines and critical illness outcomes. J Trauma Acute Care Surg 2017
[Crossref] 15. Demiray G, Değirmencioğlu S, Uğurlu E, et al. Effects of serum leptin and resistin levels on cancer cachexia in patients with advanced-stage non-small cell lung cancer. Clin Med Insights Oncol 2017
DOI: 10.1177/1179554917690144. [Crossref] 16. Qu X, Han L, Wang S, et al. Detection of chemerin and it's clinical significance in peripheral blood of patients with lung cancer. Zhongguo Fei Ai Za Zhi 2009